Department of Medical Genetics, The Lady Davis Institute, Jewish General Hospital, 3755 Cote St. Catherine Road, Montreal, QC, H3T 1E2, Canada.
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Acta Neuropathol. 2021 Jun;141(6):929-944. doi: 10.1007/s00401-021-02283-6. Epub 2021 Mar 1.
Pituitary blastoma (PitB) has recently been identified as a rare and potentially lethal pediatric intracranial tumor. All cases that have been studied molecularly possess at least one DICER1 pathogenic variant. Here, we characterized nine pituitary samples, including three fresh frozen PitBs, three normal fetal pituitary glands and three normal postnatal pituitary glands using small-RNA-Seq, RNA-Seq, methylation profiling, whole genome sequencing and Nanostring® miRNA analyses; an extended series of 21 pituitary samples was used for validation purposes. These analyses demonstrated that DICER1 RNase IIIb hotspot mutations in PitBs induced improper processing of miRNA precursors, resulting in aberrant 5p-derived miRNA products and a skewed distribution of miRNAs favoring mature 3p over 5p miRNAs. This led to dysregulation of hundreds of 5p and 3p miRNAs and concomitant dysregulation of numerous mRNA targets. Gene expression analysis revealed PRAME as the most significantly upregulated gene (500-fold increase). PRAME is a member of the Retinoic Acid Receptor (RAR) signaling pathway and in PitBs, the RAR, WNT and NOTCH pathways are dysregulated. Cancer Hallmarks analysis showed that PI3K pathway is activated in the tumors. Whole genome sequencing demonstrated a quiet genome with very few somatic alterations. The comparison of methylation profiles to publicly available data from ~ 3000 other central nervous system tumors revealed that PitBs have a distinct methylation profile compared to all other tumors, including pituitary adenomas. In conclusion, this comprehensive characterization of DICER1-related PitB revealed key molecular underpinnings of PitB and identified pathways that could potentially be exploited in the treatment of this tumor.
垂体胚细胞瘤(PitB)最近被确定为一种罕见且潜在致命的儿童颅内肿瘤。所有经过分子研究的病例均至少携带一种 DICER1 致病性变异。在这里,我们使用小 RNA-Seq、RNA-Seq、甲基化谱分析、全基因组测序和 Nanostring® miRNA 分析对包括三个新鲜冷冻 PitB、三个正常胎儿垂体和三个正常产后垂体在内的九个垂体样本进行了特征描述;为了验证目的,还使用了一个扩展的 21 个垂体样本系列。这些分析表明,PitBs 中的 DICER1 RNAse IIIb 热点突变导致 miRNA 前体的不当加工,从而导致异常的 5p 衍生 miRNA 产物和 miRNA 分布偏向成熟的 3p 而非 5p miRNA。这导致数百个 5p 和 3p miRNA 的失调以及许多 mRNA 靶标的失调。基因表达分析显示 PRAME 是上调最显著的基因(上调 500 倍)。PRAME 是维甲酸受体(RAR)信号通路的成员,在 PitBs 中,RAR、WNT 和 NOTCH 通路失调。癌症特征分析表明,PI3K 通路在肿瘤中被激活。全基因组测序表明基因组非常安静,体细胞改变很少。将甲基化谱与来自约 3000 个其他中枢神经系统肿瘤的公开数据进行比较表明,与所有其他肿瘤(包括垂体腺瘤)相比,PitBs 具有独特的甲基化谱。总之,对 DICER1 相关 PitB 的全面特征描述揭示了 PitB 的关键分子基础,并确定了可能在该肿瘤治疗中被利用的途径。